|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.47 USD | +0.91% |
|
+3.19% | +35.42% |
| 07-17 | CVS Health Opens Pharmacy-Focused Location in Houston | MT |
| 07-17 | Cvs Health Unveils First Pharmacy-Focused Cvs Pharmacy Location in Houston | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.71 | 4.18 | 3.68 | 1.99 | 2.47 | |||||
Return on Total Capital | 5.63 | 6.57 | 5.89 | 3.19 | 3.99 | |||||
Return On Equity % | 10.89 | 5.68 | 11.28 | 6.02 | 2.29 | |||||
Return on Common Equity | 10.95 | 5.68 | 11.28 | 6.07 | 2.35 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 17.48 | 16.62 | 14.94 | 13.29 | 13.29 | |||||
SG&A Margin | 12.74 | 11.83 | 10.99 | 11.12 | 10.78 | |||||
EBITDA Margin % | 6.29 | 6.11 | 5.17 | 3.4 | 3.66 | |||||
EBITA Margin % | 5.51 | 5.36 | 4.48 | 2.71 | 3 | |||||
EBIT Margin % | 4.74 | 4.79 | 3.95 | 2.16 | 2.51 | |||||
Income From Continuing Operations Margin % | 2.71 | 1.29 | 2.35 | 1.24 | 0.43 | |||||
Net Income Margin % | 2.72 | 1.29 | 2.34 | 1.24 | 0.44 | |||||
Net Avail. For Common Margin % | 2.72 | 1.29 | 2.34 | 1.24 | 0.44 | |||||
Normalized Net Income Margin | 2.68 | 2.71 | 2.19 | 1.22 | 1.44 | |||||
Levered Free Cash Flow Margin | 5.01 | 3.74 | 3.11 | 1.86 | 1.48 | |||||
Unlevered Free Cash Flow Margin | 5.55 | 4.18 | 3.57 | 2.36 | 1.97 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.25 | 1.39 | 1.49 | 1.47 | 1.58 | |||||
Fixed Assets Turnover | 8.9 | 10.25 | 11.66 | 12.49 | 14.03 | |||||
Receivables Turnover (Average Receivables) | 14.34 | 14.34 | 16.63 | 24.52 | 25.86 | |||||
Inventory Turnover (Average Inventory) | 13.24 | 14.55 | 16.35 | 17.79 | 18.56 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.88 | 0.94 | 0.86 | 0.81 | 0.84 | |||||
Quick Ratio | 0.55 | 0.62 | 0.59 | 0.56 | 0.57 | |||||
Operating Cash Flow to Current Liabilities | 0.27 | 0.23 | 0.17 | 0.11 | 0.12 | |||||
Days Sales Outstanding (Average Receivables) | 25.46 | 25.46 | 21.95 | 14.93 | 14.12 | |||||
Days Outstanding Inventory (Average Inventory) | 27.56 | 25.08 | 22.33 | 20.57 | 19.66 | |||||
Average Days Payable Outstanding | 18.06 | 18.54 | 17.95 | 17.53 | 17.59 | |||||
Cash Conversion Cycle (Average Days) | 34.96 | 31.99 | 26.33 | 17.97 | 16.19 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 100.82 | 99.18 | 103.59 | 109.49 | 106.06 | |||||
Total Debt / Total Capital | 50.2 | 49.79 | 50.88 | 52.27 | 51.47 | |||||
LT Debt/Equity | 93.06 | 94.34 | 97.44 | 99.6 | 98.36 | |||||
Long-Term Debt / Total Capital | 46.34 | 47.36 | 47.86 | 47.54 | 47.73 | |||||
Total Liabilities / Total Assets | 67.65 | 68.76 | 69.31 | 70.09 | 70.27 | |||||
EBIT / Interest Expense | 5.5 | 6.74 | 5.29 | 2.71 | 3.21 | |||||
EBITDA / Interest Expense | 8.59 | 9.98 | 8.11 | 5.29 | 5.66 | |||||
(EBITDA - Capex) / Interest Expense | 7.58 | 8.79 | 6.97 | 4.35 | 4.75 | |||||
Total Debt / EBITDA | 3.54 | 3.1 | 3.68 | 5.3 | 4.53 | |||||
Net Debt / EBITDA | 2.95 | 2.41 | 3.15 | 4.6 | 3.93 | |||||
Total Debt / (EBITDA - Capex) | 4.01 | 3.52 | 4.28 | 6.45 | 5.4 | |||||
Net Debt / (EBITDA - Capex) | 3.34 | 2.74 | 3.67 | 5.59 | 4.68 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.59 | 10.56 | 10.88 | 3.93 | 7.87 | |||||
Gross Profit, 1 Yr. Growth % | 5.39 | 5.13 | -0.72 | -7.56 | 7.88 | |||||
EBITDA, 1 Yr. Growth % | 1.02 | 5.99 | -7.65 | -31.58 | 15.92 | |||||
EBITA, 1 Yr. Growth % | 0.2 | 5.68 | -8.84 | -37.14 | 19.42 | |||||
EBIT, 1 Yr. Growth % | 0.83 | 9.81 | -10.6 | -43.02 | 24.94 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 9.68 | -47.27 | 93.39 | -45.2 | -62.32 | |||||
Net Income, 1 Yr. Growth % | 10.18 | -47.55 | 93.55 | -44.7 | -61.68 | |||||
Normalized Net Income, 1 Yr. Growth % | 8.39 | 9.31 | -12.2 | -42.08 | 26.72 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 8.78 | -47.23 | 98.47 | -43.43 | -62.02 | |||||
Accounts Receivable, 1 Yr. Growth % | 7.66 | 13.24 | -42.73 | -6.47 | 11.66 | |||||
Inventory, 1 Yr. Growth % | -3.98 | 7.49 | -5.58 | 0.45 | 6.29 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -3.95 | -3.98 | -1.01 | -4.92 | -3.04 | |||||
Total Assets, 1 Yr. Growth % | 0.99 | -2.03 | 9.4 | 1.4 | 0.13 | |||||
Tangible Book Value, 1 Yr. Growth % | -19.93 | -3.58 | 39.9 | -2.29 | -16.88 | |||||
Common Equity, 1 Yr. Growth % | 8.19 | -5.41 | 6.98 | -1.18 | -0.46 | |||||
Cash From Operations, 1 Yr. Growth % | 15.13 | -11.43 | -17.01 | -32.17 | 16.82 | |||||
Capital Expenditures, 1 Yr. Growth % | 3.41 | 8.21 | 11.15 | -8.25 | 1.83 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 13.21 | -18.42 | -7.21 | -37.62 | -14.18 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 9.86 | -17.48 | -4.7 | -31.24 | -10.04 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 10 | 10 | 9.92 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.65 | 9.57 | 10.72 | 7.35 | 5.89 | |||||
Gross Profit, 2 Yr. CAGR % | 6.88 | 5.26 | 2.29 | -4.2 | -0.14 | |||||
EBITDA, 2 Yr. CAGR % | 6.29 | 4.22 | -0.55 | -20.51 | -10.94 | |||||
EBITA, 2 Yr. CAGR % | 6.07 | 3.74 | -1.26 | -24.3 | -13.36 | |||||
EBIT, 2 Yr. CAGR % | 7.97 | 6.22 | -0.3 | -28.63 | -15.62 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 9.14 | -23.95 | 2.34 | 2.95 | -54.56 | |||||
Net Income, 2 Yr. CAGR % | 9.19 | -23.98 | 2.12 | 3.45 | -53.97 | |||||
Normalized Net Income, 2 Yr. CAGR % | 12.93 | 9.99 | -1.35 | -28.69 | -14.33 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.22 | -24.23 | 3.67 | 5.96 | -53.65 | |||||
Accounts Receivable, 2 Yr. CAGR % | 10.49 | 10.41 | -13.84 | -26.81 | 2.2 | |||||
Inventory, 2 Yr. CAGR % | 0.69 | 1.59 | 0.74 | -2.61 | 3.33 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -1.36 | -3.96 | -2.5 | -2.98 | -3.99 | |||||
Total Assets, 2 Yr. CAGR % | 2.34 | -0.53 | 3.53 | 5.32 | 0.76 | |||||
Tangible Book Value, 2 Yr. CAGR % | -17.85 | -12.13 | 15.4 | 16.91 | -9.88 | |||||
Common Equity, 2 Yr. CAGR % | 8.42 | 1.16 | 0.92 | 2.82 | -0.82 | |||||
Cash From Operations, 2 Yr. CAGR % | 19.23 | 0.98 | -14.26 | -24.97 | -10.98 | |||||
Capital Expenditures, 2 Yr. CAGR % | 1.27 | 5.78 | 9.67 | 0.99 | -3.34 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 19.67 | -3.36 | -13.44 | -23.92 | -26.83 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 15.62 | -4.3 | -11.73 | -19.05 | -21.35 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 4.88 | 10 | 9.96 | 4.84 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 14.48 | 7.94 | 10 | 8.41 | 7.52 | |||||
Gross Profit, 3 Yr. CAGR % | 18.09 | 6.29 | 3.36 | -1.11 | -0.33 | |||||
EBITDA, 3 Yr. CAGR % | 12.72 | 6.7 | 0.61 | -12.21 | -9.86 | |||||
EBITA, 3 Yr. CAGR % | 13.19 | 6.51 | -0.05 | -15.06 | -11.88 | |||||
EBIT, 3 Yr. CAGR % | 11.08 | 9.27 | 0.99 | -17.26 | -13.98 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 136.64 | -14.36 | 5.13 | -16.89 | -26.36 | |||||
Net Income, 3 Yr. CAGR % | 137.03 | -14.48 | 5.14 | -16.76 | -25.7 | |||||
Normalized Net Income, 3 Yr. CAGR % | 15.56 | 12.49 | 2.82 | -17.39 | -13.62 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 118.31 | -14.82 | 5.76 | -15.28 | -24.73 | |||||
Accounts Receivable, 3 Yr. CAGR % | 9.4 | 11.4 | -7.19 | -11.45 | -15.74 | |||||
Inventory, 3 Yr. CAGR % | 2.59 | 2.91 | -0.86 | 0.65 | 0.27 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 41.3 | -2.24 | -2.99 | -3.32 | -3 | |||||
Total Assets, 3 Yr. CAGR % | 5.85 | 0.87 | 2.67 | 2.81 | 3.56 | |||||
Tangible Book Value, 3 Yr. CAGR % | -16.58 | -13.34 | 2.16 | 9.17 | 4.35 | |||||
Common Equity, 3 Yr. CAGR % | 8.84 | 3.6 | 3.29 | 0.21 | 1.72 | |||||
Cash From Operations, 3 Yr. CAGR % | 27.25 | 7.98 | -5.41 | -20.7 | -13.04 | |||||
Capital Expenditures, 3 Yr. CAGR % | 7.35 | 3.54 | 7.54 | 3.34 | 1.27 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.02 | 5.72 | -4.88 | -22.4 | -20.8 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 4.31 | 3.67 | -4.64 | -18.78 | -16.15 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 3.23 | 6.56 | 9.97 | 6.53 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.38 | 11.72 | 12.96 | 7.7 | 8.34 | |||||
Gross Profit, 5 Yr. CAGR % | 11.99 | 13.4 | 11.53 | 2.04 | 1.95 | |||||
EBITDA, 5 Yr. CAGR % | 6.98 | 9.93 | 7.63 | -4.86 | -4.18 | |||||
EBITA, 5 Yr. CAGR % | 7.12 | 10.22 | 7.64 | -6.76 | -5.6 | |||||
EBIT, 5 Yr. CAGR % | 5.43 | 9.55 | 6.96 | -7.46 | -6.02 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 8.22 | -8.88 | 69.62 | -7.11 | -24.83 | |||||
Net Income, 5 Yr. CAGR % | 8.27 | -8.93 | 69.64 | -7 | -24.44 | |||||
Normalized Net Income, 5 Yr. CAGR % | 5.59 | 9.82 | 9.12 | -5.82 | -4.42 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.92 | -13.41 | 62.45 | -6.35 | -23.97 | |||||
Accounts Receivable, 5 Yr. CAGR % | 11.58 | 12.82 | -0.57 | -3.25 | -3.55 | |||||
Inventory, 5 Yr. CAGR % | 3.77 | 4.53 | 1.85 | 0.67 | 0.8 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 25.77 | 24.47 | 21.81 | -2.54 | -3.39 | |||||
Total Assets, 5 Yr. CAGR % | 19.79 | 19.13 | 4.92 | 2.62 | 1.9 | |||||
Tangible Book Value, 5 Yr. CAGR % | 17.24 | 17.25 | -5.02 | -2.57 | -2.84 | |||||
Common Equity, 5 Yr. CAGR % | 15.31 | 13.51 | 5.6 | 3.42 | 1.63 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.49 | 15.1 | 8.66 | -6.65 | -7.68 | |||||
Capital Expenditures, 5 Yr. CAGR % | 2.53 | 7.29 | 8.27 | 2.51 | 3.05 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 13.32 | 15.4 | -2.52 | -7.45 | -14.36 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 13.75 | 15.52 | -2.18 | -6.22 | -11.71 | |||||
Dividend Per Share, 5 Yr. CAGR % | 3.3 | 1.92 | 3.89 | 5.87 | 5.87 |
- Stock Market
- Stocks
- CVS Stock
- Financials CVS Health Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















